This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

VAXNEUVANCE is a CDC recommended option for all of your appropriate pediatric patients1

The CDC, AAP, and AAFP recommend the use of VAXNEUVANCE as an option for routine vaccination in infants and children, as well as for vaccination in children with certain medical conditions.1-3

A CDC recommended option1

The ACIP recommends VAXNEUVANCE (PCV15) and PCV20 at parity for routine vaccination of healthy pediatric patients

CDC recommendation on interchangeability1

VAXNEUVANCE is a CDC recommended option for a 4-dose series or for completion of a 4-dose series initiated with another PCV

Proactively studied in certain at-risk populations1-3,a

VAXNEUVANCE is a CDC, AAP, and AAFP recommended PCV with specifically designed clinical studies of pediatric populations with certain risk conditions

When choosing a vaccine for your appropriate pediatric patients, including those with certain immunocompromising conditions who may struggle to mount an adequate immune response, choose the robust immunogenicity of VAXNEUVANCE.4-6,a

aPediatric populations with risk conditions were preterm infants, children living with HIV or SCD (immunocompromising diseases), or children who had received an allo-HSCT (an immunocompromising condition): preterm infants, <37 weeks gestation at birth; children living with HIV, 6–17 years of age; children living with SCD, 5–17 years of age; and recipients of allo-HSCT, 3–17 years of age.7

VAXNEUVANCE is available through the VFC Program8

You have brand choice—choose VAXNEUVANCE for your patients enrolled in the Vaccines for Children Program.8,9

Parents and caregivers of your pediatric patients may be unaware of vaccination programs, such as the VFC Program. VFC is a federally funded vaccine program that provides recommended vaccines to eligible children and adolescents who might not otherwise be able to afford them.9

As of December 2024,

100%*

of commercially insured pediatric patients are insured by a plan that has approved coverage for VAXNEUVANCE10,b,c

bTotal Medical Lives (N=140,526,677) and VAXNEUVANCE Covered Lives (N=140,526,677).

cData, from Clarivate, are as of December 2024 and reflect coverage under the commercial medical benefit.

*Payers with coverage as N/A (not available/confirmed) have been removed from both the Total Medical Lives and the VAXNEUVANCE Covered Lives, and therefore are not represented in this percentage.

The information reflected here is subject to change at any time.

Additionally, this information is not inclusive of all plans that have made a decision regarding coverage for VAXNEUVANCE. You should contact your patient’s health plan directly for information on coverage and out-of-pocket costs to ensure that you have the most timely and accurate information.

The information provided does not guarantee that a decision on coverage will result in out-of-pocket costs being covered.

Coverage for VAXNEUVANCE is dependent on the terms and conditions of your patient’s insurance benefit, including any applicable deductible or cap. Additionally, there may be a co-pay or coinsurance that applies. A health plan’s decision to cover VAXNEUVANCE does not guarantee that implementation at the regional/local level has occurred or will necessarily occur.

Looking to stock VAXNEUVANCE in your practice?

Simply register or log into your account to get started.

Order VAXNEUVANCE

AAP, American Academy of Pediatrics; AAFP, American Academy of Family Physicians; ACIP, Advisory Committee on Immunization Practices; allo-HSCT, allogeneic hematopoietic stem cell transplant; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; PCV; pneumococcal conjugate vaccine; PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; SCD, sickle cell disease; VFC, Vaccines for Children.

View safety & tolerability data

View safety & tolerability data

Discover resources for your practice and patients

Discover resources for your practice and patients

Stay updated on serotypes

Stay updated on serotypes

Get details on first year of life

Get details on first year of life

References:

  1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States 2025. Updated November 21, 2024. Accessed December 2, 2024. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
  2. AAP. Vaccination recommendations by the AAP. Last updated September 16, 2024. Accessed October 29, 2024. https://www.aap.org/en/patient-care/immunizations/vaccination-recommendations-by-the-aap/?srsltid=AfmBOoofcAhavCOfwUxPrbISOhI3G57dh2NQE2poIv6EFmt7VZFEjoM
  3. Immunization schedules. American Academy of Family Physicians. 2025. Accessed January 14, 2025. https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules.html
  4. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children – an overview for physicians. Eur J Pediatr. 2021;180(7):2035-2047. doi:10.1007/s00431-021-03997-1
  5. Quinn CT, Wiedmann RT, Jarovsky D, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Adv. 2023;7(3):414-421. doi:10.1182/bloodadvances.2022008037
  6. Altered immunocompetence. General best practice guidelines for immunization. Centers for Disease Control and Prevention. Updated August 1, 2023. Accessed May 30, 2024. https:// www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html
  7. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 9, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
  8. Centers for Disease Control and Prevention (CDC). VFC. CDC Vaccine Price List. Updated April 1, 2025. Accessed April 3, 2025. https://www.cdc.gov/vaccines-for-children/php/awardees/current-cdc-vaccine-price-list.html
  9. Centers for Disease Control and Prevention. About the Vaccines for Children (VFC) Program. Reviewed June 26, 2024. Accessed September 6, 2024. https://www.cdc.gov/vaccines-for-children/about/?CDC_AAref_Val=https://www.cdc.gov/vaccines/programs/vfc/about/index.html
  10. Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-PVC-02062.
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.